Testspace
Atezolizumab (anti-PD-L1-Antibody) | Avelumab (anti-PD-L1-Antibody) | Cemiplimab (anti-PD-1-Antibody) | Durvalumab (anti-PD-L1-Antibody) | Ipilimumab (anti-CTLA-4-Antibody) | Nivolumab (anti-PD-1-Antibody) | Nivolumab+ Relatlimab (anti-PD-L1-Antibody+anti-LAG-3-Antibody) | Pembrolizumab (anti-PD-1-Antibody) | Tislelizumab (anti-PD-L1-Antibody) | ||
| Lung | ||||||||||
| NSCLC | 1L | |||||||||
| 2L | ||||||||||
| Stage III | ||||||||||
Last Update: 27. April 2026